Detailed explanation of the indications and types of diseases that can be treated with Ivonib (Tosovo)

Ivosidenib is an oral small molecule targeted drug that mainly acts on tumors with IDH1 (isocitrate dehydrogenase 1) mutations. By selectively inhibiting mutant IDH1, ivonib can block the production of abnormal metabolites 2‑HG (2‑hydroxyglutarate), restore the tumor cell differentiation process, and inhibit tumor proliferation. The drug is one of the first precision therapeutic drugs targeting IDH1 mutations and is suitable for a variety of hematological and solid tumors related to IDH1 mutations. It especially shows unique advantages in patients with limited efficacy of traditional treatments.

In hematological tumors, ivonib is mainly used to treat patients with relapsed or refractory acute myeloid leukemia (R/R AML) with positive IDH1 mutations. Clinical studies have shown that ivonib can significantly improve the complete remission rate (CR) of these patients, and some patients can even achieve long-term remission without transplantation. At the same time, the drug shows good tolerance in relapsed or refractory AML. Compared with traditional chemotherapy, its incidence of bone marrow suppression and serious infection is significantly reduced, providing a feasible treatment option for elderly or weak patients.

In addition to hematological tumors, ivonib is also undergoing exploratory research in IDH1 mutated high-grade gliomas and certain solid tumors (such as cholangiocarcinoma, gliomas). In these indications, drugs can delay tumor progression and alleviate symptoms by inhibiting abnormal metabolic pathways and improving cell differentiation status. Although the current clinical efficacy data on solid tumors are still in the early stages, multiple clinical trials have shown that ivonib can stabilize tumor burden and achieve disease remission in some patients, providing a basis for future expansion of indications.

In general, the indications of Ivosidenib (Ivosidenib) cover IDH1 mutated relapsed or refractory acute myeloid leukemia, and its application potential in solid tumors such as glioma and cholangiocarcinoma is being studied. By precisely targeting mutant IDH1, the drug can improve tumor cell differentiation, inhibit proliferation, and improve clinical response rates while ensuring safety. In the future, as more research data accumulates, the application prospects of ivonib in patients with hematological tumors and specific solid tumors will be broader, providing strong support for precision medicine.

Keyword tag:

Indications, IDH1 mutation, acute myeloid leukemia (AML), solid tumors, cholangiocarcinoma, glioblastoma, precision therapy, targeted drugs, differentiation syndrome, routine blood monitoring

Reference:https://reference.medscape.com/drug/tibsovo-ivosidenib-1000240